Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Depreciation & Amortization (CF): 2020-2024

Historic Depreciation & Amortization (CF) for Monte Rosa Therapeutics (GLUE) over the last 5 years, with Dec 2024 value amounting to $8.1 million.

  • Monte Rosa Therapeutics' Depreciation & Amortization (CF) fell 0.38% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 5.31%. This contributed to the annual value of $8.1 million for FY2024, which is 30.52% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $8.1 million for FY2024, which was up 30.52% from $6.2 million recorded in FY2023.
  • Monte Rosa Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $8.1 million for FY2024, and its period low was $537,000 during FY2020.
  • Its 3-year average for Depreciation & Amortization (CF) is $6.0 million, with a median of $6.2 million in 2023.
  • Data for Monte Rosa Therapeutics' Depreciation & Amortization (CF) shows a peak YoY spiked of 297.02% (in 2021) over the last 5 years.
  • Over the past 5 years, Monte Rosa Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $537,000 in 2020, then soared by 297.02% to $2.1 million in 2021, then skyrocketed by 75.66% to $3.7 million in 2022, then spiked by 66.14% to $6.2 million in 2023, then soared by 30.52% to $8.1 million in 2024.